This study is led by Prof. Kenneth To (School of Pharmacy, The Chinese University of Hong Kong) and Dr. William Cho ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib after they fail to respond to ...

DefectDojo, the pioneer in scalable security, unified vulnerability management and DevSecOps, today announced the winners of its inaugural Open-Source Security Awards. These awards recognize the most ...

ThinkLP, the leading Loss & Safety Intelligence Platform, today announced the launch of AI Crime Linking, enhancing its Complex Investigations product. This powerful new solution is designed to track ...

Kairos Pharma (NYSE American: KAPA) announced that the U.S. Department of Defense has awarded $876,000 to Cedars-Sinai Medical Center to support bio ...

Cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022.

and AbbVie is looking specifically at this group in a phase 1 study that is looking at the combination of Teliso-V and AstraZeneca's EGFR inhibitor Tagrisso (osimertinib), to see if the ADC can ...

"Backed by interim overall survival data showing a strong favourable trend compared to osimertinib, we believe strongly in the robust efficacy and safety of Rybrevant – both as a standalone ...

ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I ...

University of Kentucky Markey Cancer Center researchers will present their latest scientific advancements at the American ...

According to Research by SNS Insider, Global Prostate Cancer Diagnostics Market Growth is Fueled by Growing Demand for Advanced Biomarker Testing, AI Diagnostics, and Outpatient Screening Services ...